From pipeline to product: Malaria R&D funding needs into the next decade

10 Dec 2013

A report authored by Policy Cures, an independent nonprofit research group, with input and funding from several malaria-focused product development partnerships

From Pipeline to Product: Malaria R&D funding needs into the next decade serves as a tool to guide policymakers’ investment in new tools to control malaria, contain emerging threats, and move toward the goal of eradicating malaria from the world. It looks at the estimated funding needed for R&D of new malaria tools until 2022, including for basic research, drugs, vaccines, diagnostics, and vector control agents. The report provides an update to the 2011 Staying the Course report, which estimated R&D cost and R&D investments for all malaria R&D activities.